Contributions
Abstract: EP1467
Type: Poster Sessions
Abstract Category: Pathology and pathogenesis of MS - Genetics/Epigenetics
Background: Long non-coding RNAs (lncRNAs) have been reported to be involved in the pathogenesis of various human diseases, however, few studies had investigated the potential link between lncRNAs and MS pathology. The aim of the study was to study the expression of long noncoding RNA-Ccr2-5As and THRIL (TNF alpha and heterogenous nuclear ribonucleoprotein hnRNPL) in MS patients and to correlate them with the disease progression and level of disability.
Subject and methods: Seventy two MS patients (relapsing remitting and secondary progressive types) and 30 healthy controls were recruited for the study. They were tested for Long noncoding RNA-Ccr2-5As and THRIL quantitation in serum by real time PCR.
Results: LincR-Ccr2-5'AS was found to be significantly down-regulated in MS patients as compared to controls; the decrease was ≥2 compared to controls (the fold change = 0.34, p = 0.03). On the other hand, LincRNA THRIL was significantly up-regulated in MS patients compared to controls with increase ≥ 6 fold from controls ( the fold change = 6.18 , p = 0.02). THRIL fold change was found to be higher in RRMS compared to SPMS patients (p-=0.04).
Conclusion: lincRNA-Ccr2-5As and THRIL are novel and potentially useful prognostic epigenetic biomarkers for development and progression of multiple sclerosis.
Key words: multiple sclerosis; Long noncoding RNA, biomarker, epigenetics
Disclosure: Olfat Shaker: nothing to disclose
Amr Hassan: nothing to disclose
Shereen Rashad: nothing to disclose
Asmaa M Ibrahim: nothing to disclose
Abstract: EP1467
Type: Poster Sessions
Abstract Category: Pathology and pathogenesis of MS - Genetics/Epigenetics
Background: Long non-coding RNAs (lncRNAs) have been reported to be involved in the pathogenesis of various human diseases, however, few studies had investigated the potential link between lncRNAs and MS pathology. The aim of the study was to study the expression of long noncoding RNA-Ccr2-5As and THRIL (TNF alpha and heterogenous nuclear ribonucleoprotein hnRNPL) in MS patients and to correlate them with the disease progression and level of disability.
Subject and methods: Seventy two MS patients (relapsing remitting and secondary progressive types) and 30 healthy controls were recruited for the study. They were tested for Long noncoding RNA-Ccr2-5As and THRIL quantitation in serum by real time PCR.
Results: LincR-Ccr2-5'AS was found to be significantly down-regulated in MS patients as compared to controls; the decrease was ≥2 compared to controls (the fold change = 0.34, p = 0.03). On the other hand, LincRNA THRIL was significantly up-regulated in MS patients compared to controls with increase ≥ 6 fold from controls ( the fold change = 6.18 , p = 0.02). THRIL fold change was found to be higher in RRMS compared to SPMS patients (p-=0.04).
Conclusion: lincRNA-Ccr2-5As and THRIL are novel and potentially useful prognostic epigenetic biomarkers for development and progression of multiple sclerosis.
Key words: multiple sclerosis; Long noncoding RNA, biomarker, epigenetics
Disclosure: Olfat Shaker: nothing to disclose
Amr Hassan: nothing to disclose
Shereen Rashad: nothing to disclose
Asmaa M Ibrahim: nothing to disclose